This is an RSS newsfeed from BioMed Central It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit http://www.biomedcentral.com/info/about/rss/ Current Opinion in Drug Discovery & Development - Latest articles http://thomsoncurrentdrugs.com/products/journals/coddd The latest articles from Current Opinion in Drug Discovery & Development (ISSN 1367-6733) published by Current Drugs Limited. Exploiting QSAR models in lead optimization http://www.biomedcentral.com/1367-6733/11/569 P Gedeck and RA Lewis Current Opinion in Drug Discovery & Development 2008, 11:569-575 2008-06-30 doi:10.1186/cd-921165 Current Opinion in Drug Discovery & Development 1367-6733 11 569 2008-06-30 From virtuality to reality – Virtual screening in lead discovery and lead optimization: A medicinal chemistry perspective http://www.biomedcentral.com/1367-6733/11/559 U Rester Current Opinion in Drug Discovery & Development 2008, 11:559-568 2008-06-30 doi:10.1186/cd-921161 Current Opinion in Drug Discovery & Development 1367-6733 11 559 2008-06-30 The impact of diversity-based, high-throughput screening on drug discovery: "Chance favours the prepared mind" http://www.biomedcentral.com/1367-6733/11/553 M Snowden and DVS Green Current Opinion in Drug Discovery & Development 2008, 11:553-558 2008-06-30 doi:10.1186/cd-921160 Current Opinion in Drug Discovery & Development 1367-6733 11 553 2008-06-30 Conformationally based design of macrocycles as antitumor agents http://www.biomedcentral.com/1367-6733/11/544 EK Singh, RP Sellers, LD Alexander and SR McAlpine Current Opinion in Drug Discovery & Development 2008, 11:544-552 2008-06-30 doi:10.1186/cd-921158 Current Opinion in Drug Discovery & Development 1367-6733 11 544 2008-06-30 Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic http://www.biomedcentral.com/1367-6733/11/533 M Medina and A Castro Current Opinion in Drug Discovery & Development 2008, 11:533-543 2008-06-30 doi:10.1186/cd-921159 Current Opinion in Drug Discovery & Development 1367-6733 11 533 2008-06-30 From the bench to the bedside: Dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents http://www.biomedcentral.com/1367-6733/11/512 Z Pei Current Opinion in Drug Discovery & Development 2008, 11:512-532 2008-06-30 doi:10.1186/cd-921157 Current Opinion in Drug Discovery & Development 1367-6733 11 512 2008-06-30 Recent advances in the discovery of 11b-HSD1 inhibitors http://www.biomedcentral.com/1367-6733/11/495 CD Boyle Current Opinion in Drug Discovery & Development 2008, 11:495-511 2008-06-30 doi:10.1186/cd-921156 Current Opinion in Drug Discovery & Development 1367-6733 11 495 2008-06-30 Targeting myostatin for therapies against muscle-wasting disorders http://www.biomedcentral.com/1367-6733/11/487 K Tsuchida Current Opinion in Drug Discovery & Development 2008, 11:487-494 2008-06-30 doi:10.1186/cd-921155 Current Opinion in Drug Discovery & Development 1367-6733 11 487 2008-06-30 TAFIa inhibitors in the treatment of thrombosis http://www.biomedcentral.com/1367-6733/11/480 ME Bunnage and DR Owen Current Opinion in Drug Discovery & Development 2008, 11:480-486 2008-06-30 doi:10.1186/cd-921154 Current Opinion in Drug Discovery & Development 1367-6733 11 480 2008-06-30 Integrase inhibitors for the treatment of HIV infection http://www.biomedcentral.com/1367-6733/11/471 P Pace and M Rowley Current Opinion in Drug Discovery & Development 2008, 11:471-479 2008-06-30 doi:10.1186/cd-921153 Current Opinion in Drug Discovery & Development 1367-6733 11 471 2008-06-30 Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: The development pipeline and recent clinical data http://www.biomedcentral.com/1367-6733/11/458 ZK Sweeney and K Klumpp Current Opinion in Drug Discovery & Development 2008, 11:458-470 2008-06-30 doi:10.1186/cd-921150 Current Opinion in Drug Discovery & Development 1367-6733 11 458 2008-06-30 Recent progress in the discovery of selective, non-peptide ligands of somatostatin receptors http://www.biomedcentral.com/1367-6733/11/446 SE Wolkenberg and CJ Thut Current Opinion in Drug Discovery & Development 2008, 11:446-457 2008-06-30 doi:10.1186/cd-921149 Current Opinion in Drug Discovery & Development 1367-6733 11 446 2008-06-30 Agonists of the serotonin 5-HT2C receptor: Preclinical and clinical progression in multiple diseases http://www.biomedcentral.com/1367-6733/11/438 DA Wacker and KJ Miller Current Opinion in Drug Discovery & Development 2008, 11:438-445 2008-06-30 doi:10.1186/cd-921148 Current Opinion in Drug Discovery & Development 1367-6733 11 438 2008-06-30 Rediscovering the role of natural products in drug discovery http://www.biomedcentral.com/1367-6733/11/436 MC Desai and S Chackalamannil Current Opinion in Drug Discovery & Development 2008, 11:436-437 2008-06-30 doi:10.1186/cd-921147 Current Opinion in Drug Discovery & Development 1367-6733 11 436 2008-06-30 Web alert http://www.biomedcentral.com/1367-6733/11/434 TDY Chung Current Opinion in Drug Discovery & Development 2008, 11:434-435 2008-06-30 doi:10.1186/cd-921146 Current Opinion in Drug Discovery & Development 1367-6733 11 434 2008-06-30 Patent alert http://www.biomedcentral.com/1367-6733/11/421 Reuters Current Awareness Analysts Thomson Current Opinion in Drug Discovery & Development 2008, 11:421-433 2008-06-30 doi:10.1186/cd-921142 Current Opinion in Drug Discovery & Development 1367-6733 11 421 2008-06-30 Paper alert http://www.biomedcentral.com/1367-6733/11/407 P Norman, DP Rotella and B Sherborne Current Opinion in Drug Discovery & Development 2008, 11:407-420 2008-06-30 doi:10.1186/cd-921141 Current Opinion in Drug Discovery & Development 1367-6733 11 407 2008-06-30 Erratum http://www.biomedcentral.com/1367-6733/11/405 Current Opinion in Drug Discovery & Development 2008, 11:405 2008-04-18 doi:10.1186/cd-898033 Current Opinion in Drug Discovery & Development 1367-6733 11 405 2008-04-18